Overexpression of Cyclooxygenase-2 in Malignant Peripheral Nerve Sheath Tumor and Selective Cyclooxygenase-2 Inhibitor-Induced Apoptosis by Activating Caspases in Human Malignant Peripheral Nerve Sheath Tumor Cells

Michiyuki Hakozaki1,2,8*, Takahiro Tajino1,8, Shinichi Konno1,8, Shinichi Kikuchi1, Hitoshi Yamada1,8, Michiro Yanagisawa3,8, Jun Nishida4,8, Hiroyuki Nagasawa5,8, Takashi Tsuchiya6,8, Akira Ogose7,8, Masafumi Abe2, Hiroshi Hojo2

1 Department of Orthopaedic Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan, 2 Department of Pathology and Diagnostic Pathology, Fukushima Medical University School of Medicine, Fukushima, Japan, 3 Department of Orthopaedic Surgery, Hirosaki University Graduate School of Medicine, Aomori, Japan, 4 Department of Orthopaedic Surgery, School of Medicine, Iwate Medical University, Iwate, Japan, 5 Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan, 6 Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan, 7 Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 8 Tohoku Musculoskeletal Tumor Society, Yamagata, Japan

Abstract

Background: Cyclooxygenase-2 (COX-2) is a key enzyme in the conversion of arachidonic acid to prostanoids, and its activation is associated with carcinogenesis as well as inflammation. The antitumor effect of selective COX-2 inhibitors has been noted in various malignancies. Malignant peripheral nerve sheath tumor (MPNST) is a rare and aggressive soft tissue sarcoma for which effective treatments have not yet been established. The purpose of this study was to investigate a potential therapeutic role of COX-2 in MPNST.

Methods: We evaluated the expression of COX-2 in 44 cases of high-grade MPNST using immunohistochemical staining and compared the staining results with the characteristics and outcome of the patients. We also investigated the antitumor effect of etodolac, a selective COX-2 inhibitor, on MPNST cells in vitro using the MPNST cell line, FMS-1.

Results: Overexpression of COX-2 (≥50% positive cells) was observed in 29 cases (65.9%), was significantly associated with a poor overall survival (P = 0.0495), and was considered an independent risk factor for a poor outcome by the results of both univariate and multivariate analysis. Etodolac induced apoptosis of FMS-1 cells through the activation of caspase-8, -9, and -3. Moreover, several caspase inhibitors significantly inhibited etodolac-induced apoptosis.

Conclusions: Selective COX-2 inhibitors including etodolac had an antitumor effect on MPNST cells, and their use holds promise as a novel therapeutic strategy for patients with MPNST to improve their prognoses.

Introduction

Malignant peripheral nerve sheath tumor (MPNST), also called malignant schwannoma or neurofibrosarcoma, is a rare soft tissue sarcoma, accounting for approximately 5% of soft tissue sarcomas. Approximately half of MPNSTs manifest in patients with neurofibromatosis type 1 (NF1; von Recklinghausen disease) [1], and patients with NF1 have a 5–10% lifetime risk of MPNST [2,3]. MPNST frequently shows highly aggressive behavior, resistance to multi-agent chemotherapy and radiation therapy, and fatal metastasis. About 60% of patients with MPNST die of this disease, and the overall 5- and 10-year survival rates are 34% and 23%, respectively [1]. New therapeutic developments including molecular-targeting drugs based on molecular genetic and biological characterizations of MPNST are required to improve the aggressive course and fatal prognosis of this disease.
Cyclooxygenase (COX), also known as prostaglandin H2 synthase or prostaglandin endoperoxide synthase, is a key enzyme in the conversion of arachidonic acid to prostanooids [4]. COX-2 is one of two COX types, the other being COX-1. COX-2 is undetectable in most normal tissues, but it can be induced in various cell types by pro-inflammatory agents, growth factors, and carcinogens [5]. Overexpression of COX-2 and its association with worse prognosis in various malignancies, especially in bone and soft tissue sarcomas [6–10], has been reported. COX-2 activation leads to the enhancement of cell proliferation and migration, suppression of apoptosis, stimulation of neovascularization, and alteration of intercellular adhesion, all of which are involved in carcinogenesis [11]. There have been several reports on the antitumor effects of some selective COX-2 inhibitors for bone and soft tissue sarcoma cells, including the induction of apoptosis [12–21]. However, overexpression of COX-2 in human MPNST and the antitumor effect of the selective COX-2 inhibitors on the growth of human MPNST cells have not been analyzed in detail.

In this study, we examined the expression of the COX-2 protein in human high-grade MPNST specimens by immunohistochemical techniques and analyzed the relationship between COX-2 overexpression and prognosis. In addition, we examined the antitumor effect of inducing apoptosis through caspase activation by a selective COX-2 inhibitor, etodolac, on a human MPNST cell line in vitro.

**Results**

**Association of COX-2 Overexpression with Clinical and Pathological Features**

The results are summarized in Table 1. COX-2 was expressed in 41 (93.2%) patients, and COX-2 overexpression (immunohistochemical score 3+ and 4+) was observed in 29 (65.9%) of the 44 patients based on the immunohistochemical score: 0, 3 cases; 1+, 2 cases; 2+, 10 cases; 3+, 15 cases; and 4+ in the 14 cases. COX-2 staining in the MPNSTs was consistently observed in the tumor cells with a strong and cytoplasmic pattern (Figure 1).

Statistical analysis indicated that COX-2 overexpression was significantly associated with the patient age (<50 versus ≥50 years) (P = 0.04) and background of NF1 (P = 0.01) (Table 1). There were no significant differences between COX-2 overexpression and the other variables, including sex, anatomical site (trunk versus limb), depth (deep-seated versus superficial), size (< 10 versus ≥10 cm), association with peripheral nerve, and distant metastasis at time of diagnosis (Table 1).

Log-rank analysis revealed that COX-2 overexpression was significantly associated with a decreased probability of overall survival (P = 0.0495) (Table 2 and Figure 2). The probability of survival at 5 years was 35.5% or 56.3% in patients with or without COX-2 overexpression, respectively (Table 2 and Figure 2). Each of the following was also associated with poor prognosis from the result of log-rank analysis: the location in deep tissue, large tumor size (≥10 cm), the presence of distant metastasis at the time of diagnosis, non-curative surgical treatment, and additional treatment with chemotherapy (Table 2).

Several variables were tested to assess whether they affected overall survival. The univariate and multivariate analyses with the Cox proportional hazards model revealed that large tumor size (≥10 cm), the presence of distant metastasis at the time of diagnosis, non-curative surgical treatment, and COX-2 overexpression were independent risk factors for poor outcome (Table 3). The location in deep tissue and treatment with chemotherapy were not significantly associated with poor prognosis by univariate or multivariate analysis (data not shown).

**Etodolac-induced Cell Death in vitro**

In the undifferentiated pleomorphic sarcoma (UPS) cell line, FMS-1 [22], cell viability was significantly inhibited at only higher concentration and longer period. Conversely, the MPNST cell line, FMS-1 [23], cell growth was inhibited in a dose-dependent manner, and cell viability was significantly inhibited at all times (Figure 3).

**Morphological Analysis and DNA Fragmentation Analysis of Dead Cells**

Although May-Giemsa staining of FMS-1 cells showed no morphological change, FMS-1 cells showed nuclear fragmentation in the dead cells after 72 h of etodolac treatment (Figure 4A, B, D, E). Agarose gel electrophoresis of extracted DNA samples from the dead cells revealed a DNA ladder, indicating apoptosis in FMS-1 cells (Figure 4F), but not in FMS-1 cells (Figure 4C).

**Activation of Caspase-8, -9, and -3 with Etdolac Treatment**

Both FMS-1 and FMS-1 cells treated with etodolac showed significant activation of caspase-8, -9, and -3 at 24 or 48 h compared with the control group, which was not treated with etodolac. However, the differences of caspase-activities were much smaller in FMS-1 cells than those in FMS-1 cells (Figure 5).

**Inhibition of Apoptosis by Caspase Inhibitors**

Each of the caspase inhibitors, Z-VAD-FMK (a broad caspase inhibitor), Ac-LEHD-CHO (a caspase-8 inhibitor), Ac-IETD-CHO (a caspase-9 inhibitor), and Ac-DMQD-CHO (a caspase-3 inhibitor), incompletely but significantly inhibited etodolac-induced apoptosis of FMS-1 cells. Conversely, in FMS-1 cells, only Z-VAD-FMK and Ac-LEHD-CHO significantly inhibited etodolac-induced apoptosis (Figure 6).

**Discussion**

The correlation of COX-2 overexpression with prognosis in human bone and soft tissue sarcomas has been reported previously. Although some investigators have affirmed the correlation of COX-2 overexpression with poor prognosis in some sarcomas, including osteosarcoma [7–9], chondrosarcoma [6], and uterine leiomyosarcoma [10], other investigators have denied the association in bone and soft tissue sarcomas [24–29]. The result of the present study provides the first immunohistochemical evidence that COX-2 overexpression in MPNST is significantly associated with decreased overall survival (P = 0.0495). Moreover, both the univariate and the multivariate analyses revealed that COX-2 overexpression was an independent risk factor for the poor outcome of patients with MPNST. Therefore, the immunohistochemical analysis of COX-2 in MPNST might provide useful prognostic information.

From the review of previous multivariate analyses, we conclude that large tumor size [30,31], the presence of distant metastasis at the time of diagnosis [31], inadequate surgical treatment (without a wide margin) [30,32,33], and not receiving radiation therapy [30,32] were major unfavorable prognostic factors. In the present study, the multivariate analysis indicated that large tumor size, the presence of distant metastasis at the time of diagnosis, and inadequate surgical treatment were independent risk factors, whereas treatment with radiation therapy did not significantly
correlate with poor prognosis. Most of the patients in the present study received radiation therapy as additional treatment after the surgical treatment without a wide margin or as palliative treatment for an inoperable tumor. These radiation therapies did not seem to improve the prognoses in the patients included in the present study.

Though tumor location in the trunk and tumor in the deep tissue are known as risk factors correlated with an unfavorable prognosis in the soft tissue sarcomas [34], the certain association of these factors with an unfavorable outcome in MPNST was controversial in the previous studies employing multivariate analysis; Anghilevi et al. [30] and Endo et al. [35] reported location in the trunk as a poor prognostic factor, whereas Okada et al. [31] and Wong et al. [32] did not show this association; Endo et al. [35] had also reported the association of deep-seated tumors with poor outcome, whereas Anghilevi et al. [30] and Okada et al. [31] did not show this correlation. Likewise, the result of the present study did not show a relationship between the location, including trunk location and depth, and poor overall survival. Therefore, we could not draw a conclusion about the clinical significance of the location either in the trunk or in the deep tissue as a prognostic factor of overall survival in MPNST. Further investigation with a larger number of cases or systematic review of the previous articles will be needed to solve this problem.

There are previously advocated reasons for the correlation of poor prognosis with COX-2 overexpression in many malignant diseases. COX-2 promotes malignancy through direct and indirect mechanisms, that is, prostaglandins may directly stimulate mitogenesis through a direct effect on fibroblasts, while COX-2 indirectly affects mutagenesis, angiogenesis, increased cell migration, and apoptosis, and it even affects the activity of cells with cytotoxic function, all which regulate the ability of malignant cells to survive [36,37]. Thus, elevated COX-2 expression is often correlated with decreased survival of patients with malignancies. The results of the present study indicate that the avoidance of apoptosis seems to be related to survival and the progression in FMS-1, and this may lead to poor overall survival in patients with MPNST.

The present study also revealed that etodolac, a selective COX-2 inhibitor, induced cell death in the MPNST cell line, FMS-1, and this death was demonstrated to be apoptotic by the results of a morphological examination (apoptotic body), agarose gel electrophoresis (DNA ladder), and evaluation of caspase activation and efficacy of caspase-blockage. Usually, caspase-dependent apoptosis occurs through two main interconnected pathways, which are intrinsic and extrinsic pathways. The intrinsic pathway or intracellular path is mediated by the Bcl-2 family, whereas the death receptor or extrinsic pathway is activated by signals from other cells [38]. In the intrinsic pathway, progression through the pathway usually leads to activation of caspase-9. On the other hand, activation of caspase-8 occurs in the extrinsic pathway. The activated caspase-9 or -8 then cleaves procaspase-3, giving activated caspase-3, which acts as an executioner of apoptosis.

The apoptotic event was shown to occur in FMS-1 cells through the activation of caspase-8, -9, and -3, as these caspases were activated in the FMS-1 cells treated with etodolac. Additionally, etodolac-induced apoptosis was inhibited by each caspase inhibitor, broad caspase inhibitor Z-VAD-FMK, caspase-8 inhibitor Ac-IETD-CHO, caspase-9 inhibitor Ac-LEHD-CHO, and caspase-3 inhibitor Ac-DMQD-CHO. Therefore, the results of the present study suggest that the caspase cascade of etodolac-induced apoptosis of FMS-1 cells may involve both intrinsic and extrinsic pathways. The results of the present study also suggest that there are other pathways independent of caspase activation, because the efficacy of the broad caspase inhibitor Z-VAD-FMK was incomplete. Although the UPS cell line, FPS-1, also showed COX-2 overexpression [22], the efficacy of etodolac was different from that in FMS-1. There have been several reports on the
molecular mechanisms or factors involved in selective COX-2 inhibitor-induced apoptosis; down-regulation in bcl-2 protein expression [39], augmentation of TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis [40], augmentation of Fas-mediated apoptosis [41], activation of the cytochrome c-dependent pathway [42], blocking of Akt activation [43], and increase in arachidonic acid and ceramide [44]. In addition, apoptotic pathways in the selective COX-2 inhibitor-induced apoptosis of tumor cells depend on tumor cell types or selective COX-2 inhibitor types. However, the signaling pathways from the first signal initiated by etodolac to caspase activation have not been sufficiently elucidated. Therefore, it is necessary to investigate how caspase activation occurs in FMS-1 cells and to determine whether there are other pathways independent from caspase activation, as well as to evaluate the anti-tumor effect of selective COX-2 inhibitors in other MPNST cell lines in future research.

Clinically, the antitumor effect of NSAIDs, including selective COX-2 inhibitors, for the treatment or prevention of some carcinomas has been reported [45], and the efficacy of the combination therapy with a selective COX-2 inhibitor and other chemotherapeutic agents has been reported in advanced sarcomas [46]. Therefore, the prevention of carcinogenesis of MPNST in the patients with NF1, like a colorectal cancer in the patients with familial adenomatous polyposis [45], the prevention of tumor recurrence after the surgical treatment for MPNST, as well as the

Table 1. Statistical relationship between immunohistochemical result of COX-2 and other variables.

| Variable                          | No. of patients | COX-2 overexpression | P-value |
|-----------------------------------|-----------------|-----------------------|---------|
|                                   |                 | Negative | Positive | %*     |         |
| Age (y)                           |                 |           |          |        |         |
| <50                               | 20              | 10       | 10       | 50.0   | 0.04    |
| ≥50                               | 24              | 5        | 19       | 79.2   |         |
| Sex                               |                 |           |          |        |         |
| Male                              | 21              | 9        | 12       | 57.1   | 0.24    |
| Female                            | 23              | 6        | 17       | 73.9   |         |
| NF-1                              |                 |           |          |        |         |
| Absent                            | 23              | 4        | 19       | 82.6   | 0.01    |
| Present                           | 21              | 11       | 10       | 47.6   |         |
| Relationship to peripheral nerve  |                 |           |          |        |         |
| Absent                            | 20              | 9        | 11       | 55.0   | 0.16    |
| Present                           | 24              | 6        | 18       | 75.0   |         |
| Location                          |                 |           |          |        |         |
| Trunk                             | 20              | 5        | 15       | 75.0   | 0.25    |
| Extremity                         | 24              | 10       | 14       | 58.3   |         |
| Depth                             |                 |           |          |        |         |
| Deep-seated                       | 31              | 9        | 22       | 71.0   | 0.43 (excluding NA) |
| Superficial                       | 12              | 5        | 7        | 58.3   |         |
| NA                                | 1               | 1        | 0        | 0      |         |
| Size (cm)                         |                 |           |          |        |         |
| <10                               | 22              | 8        | 14       | 63.6   | 0.75 (excluding NA) |
| ≥10                               | 19              | 6        | 13       | 68.4   |         |
| NA                                | 3               | 1        | 2        | 66.7   |         |
| Distant metastasis at time of diagnosis |     |           |          |        |         |
| Absent                            | 33              | 12       | 21       | 63.6   | 0.58    |
| Present                           | 11              | 3        | 8        | 72.7   |         |

*Percentage of positive cases; NA, not available.

doi:10.1371/journal.pone.0088035.t001

Cyclooxygenase-2 Expression in Human MPNST

**Figure 2. Kaplan-Meier curve of overall survival evaluated for COX-2 overexpression.** Overexpression of COX-2 was significantly associated with a decreased probability of overall survival (P = 0.0495). doi:10.1371/journal.pone.0088035.g002

Log-rank P = 0.0495

5-y survival rate: 56.3%

Overall survival rate: 35.5%
therapeutic effect by induction of apoptosis in the treatment of MPNST should be evaluated in future clinical investigation.

Etodolac is one of the most common selective COX-2 inhibitor and widely used all over the world for a long time (approximately 20 years). Though the risk of cardiovascular events caused by the side effect of selective COX-2 inhibitors is widely known, the risk of normal clinical dose of etodolac is still obscure because of the limited number of previous studies [47]. Thus, when we clinically use etodolac for the treatment of malignancies, we must deliberate about the risk and benefit.

Although 1 mM of etodolac (287.4 µg/ml) showed marked antitumor effect for MPNST in the present study, Cmax of the usual dose of etodolac was reported as 15.9 µg/ml (200 mg, orally) and 34.0 µg/ml (400 mg, orally) [48], much lower than the concentration used in this study. This is the limitation of this study. Further investigation with lower concentration of etodolac (e.g. 0.125 mM) will be needed.

In conclusion, we analyzed the relationship between COX-2 overexpression and prognosis in patients with MPNST. Overexpression (>50% positive cells) of COX-2 was significantly

| Variable                        | No. of patients | 5-y survival rate (%) | P-value (Log-rank test) |
|---------------------------------|-----------------|-----------------------|-------------------------|
| Age (y)                         |                 |                       |                         |
| <50                             | 20              | 40.4                  | 0.78                    |
| ≥50                             | 24              | 43.2                  |                         |
| Sex                             |                 |                       |                         |
| Male                            | 21              | 25.3                  | 0.11                    |
| Female                          | 23              | 56.3                  |                         |
| NF-1                            |                 |                       |                         |
| Absent                          | 23              | 39.9                  | 0.70                    |
| Present                         | 21              | 41.0                  |                         |
| Relationship to peripheral nerve|                 |                       |                         |
| Absent                          | 24              | 46.1                  | 0.48                    |
| Present                         | 20              | 35.5                  |                         |
| Location                        |                 |                       |                         |
| Trunk                           | 20              | 26.2                  | 0.37                    |
| Extremity                       | 24              | 49.7                  |                         |
| Depth                           |                 |                       |                         |
| Deep-seated                     | 31              | 32.2                  | 0.09 (excluding NA)    |
| Superficial                     | 12              | 66.7                  |                         |
| NA                              | 1               |                       |                         |
| Size (cm)                       |                 |                       |                         |
| <10                             | 22              | 64.3                  | 0.009 (excluding NA)   |
| ≥10                             | 19              | 22.6                  |                         |
| NA                              | 3               |                       |                         |
| Distant metastasis at time of diagnosis| |                     | <0.0001                     |
| Absent                          | 33              | 54.5                  |                         |
| Present                         | 11              | 0                     |                         |
| Surgical treatment              |                 |                       |                         |
| Curative                        | 24              | 66.1                  | 0.0002                  |
| Not curative*                   | 20              | 9.8                   |                         |
| Chemotherapy                    |                 |                       |                         |
| Yes                             | 11              | 10.4                  | 0.0434                  |
| No                              | 33              | 53.8                  |                         |
| Radiation therapy               |                 |                       |                         |
| Yes                             | 14              | 23.8                  | 0.38                    |
| No                              | 30              | 48.7                  |                         |
| COX-2 overexpression            |                 |                       |                         |
| Negative                        | 15              | 56.3                  | 0.0495                  |
| Positive                        | 29              | 35.5                  |                         |

*Including the cases in which only a biopsy was performed; NA, not available.
doi:10.1371/journal.pone.0088035.t002
associated with poor prognosis in these patients. Moreover, etodolac, a selective COX-2 inhibitor, induced apoptosis of FMS-1 cells through the activation of caspase-8, -9, and -3. Although the selective COX-2 inhibitor-induced apoptosis of some sarcoma cells has been reported previously, the present report is the first, to our knowledge, to cover the apoptosis of MPNST cells induced by the selective COX-2 inhibitor etodolac. Selective COX-2 inhibitors, including etodolac, are in widespread use as NSAIDs against inflammatory disease. The results of this study may reveal a therapeutic hypothesis in the context of a molecular chemotherapeutic approach to treating MPNST.

Materials and Methods

Tumor Samples

Forty-four Japanese patients with primary high-grade MPNST treated at university hospitals belonging to the "Tohoku Muscu-

| Variable                                      | Univariate analysis | Multivariate analysis |
|-----------------------------------------------|---------------------|-----------------------|
|                                               | Hazard ratio | 95% CI | P-value | Hazard ratio | 95% CI | P-value |
| Size (cm)                                     |             |       |        |             |       |        |
| <10                                           | 1          | 1.29–8.23 | 0.011 | 1          | 1.09–7.43 | 0.0318 |
| ≥10                                           | 3.11       |       |        | 2.72       |       |        |
| Distant metastasis at time of diagnosis       |             |       |        |             |       |        |
| Absent                                        | 1          | 2.83–18.58 | <0.0001 | 1          | 1.81–17.82 | 0.0029 |
| Present                                       | 7.20       |       |        | 5.56       |       |        |
| Surgical treatment                            |             |       |        |             |       |        |
| Curative                                      | 1          | 1.90–11.09 | 0.0005 | 1          | 1.33–11.40 | 0.0124 |
| Not curative*                                 | 4.42       |       |        | 3.75       |       |        |
| COX-2 overexpression                          |             |       |        |             |       |        |
| Negative                                      | 1          | 1.02–6.99 | 0.0456 | 1          | 1.05–10.23 | 0.0400 |
| Positive                                      | 2.49       |       |        | 3.04       |       |        |

*including the cases in which only a biopsy was performed; CI, confidence interval.

doi:10.1371/journal.pone.0088035.t003

Figure 3. Effect of etodolac treatment on FPS-1 and FMS-1 cells (n = 5). Etodolac significantly reduced cell viability of FMS-1 cells in a dose-dependent manner. P-values compared with the control were calculated based on Student's t-test (*, P < 0.05; **, P < 0.01).

doi:10.1371/journal.pone.0088035.g003
Loskeletal Tumor Society between 1992 and 2008 were included in this study. The histologic diagnosis was based on the criteria for diagnosis of MPNST previously outlined by Fletcher [49,50].

All the patients had been treated at our hospitals and followed up at our clinics. Clinical details and follow-up information were obtained by reviewing the patients' medical charts. The patients comprised 21 males and 23 females between the ages of 15 and 86 years (median, 52 years; mean, 49.8 years) and included 12 patients with familial NF1 and 9 patients with solitary NF1. The clinical diagnosis of NF1 was based on the NIH criteria [51]. In 24 cases, a relationship to the peripheral nerve was found, whereas no such relationship was seen in 20 cases. The tumors were located in the trunk in 20 cases and in the extremities in 24 cases. Twelve tumors were located superficially, 31 were deep-seated, and 1 case

Figure 4. Morphology of FPS-1 (A) and FMS-1 (D) cells after etodolac treatment for 72 h. Nuclear fragmentations were observed only in FMS-1 cells (D, arrow). Both in FPS-1 (B) and FMS-1 (E) without etodolac treatment, cells were viable and no apoptotic cells were observed (May-Giemsa staining, ×400). Evaluation of apoptosis using agarose gel electrophoresis (C, FPS-1; F, FMS-1). Only DNA samples from the FMS-1 cells (F) after etodolac treatment for 72 h revealed the DNA ladder, indicating apoptosis. M, marker, 100-bp DNA ladder; E, etodolac treatment; C, control (without etodolac treatment).

doi:10.1371/journal.pone.0088035.g004

Figure 5. Activities of caspase-8, -9, and -3 with etodolac treatment (24 and 48 h) (n = 3). Both in FPS-1 and FMS-1 cells, etodolac significantly activated caspase-8, -9, and -3 at both 24 and 48 h compared with the control group. However, the differences of caspase-activities were much smaller in FPS-1 cells than those in FMS-1 cells. P-values were calculated based on Student’s t-test (*, P<0.05; **, P<0.01).

doi:10.1371/journal.pone.0088035.g005
was uncertain. The largest diameters of the tumors ranged from 2 to 39 cm (median, 8.7 cm; mean, 10.8 cm). Distant metastasis was found in 11 cases at the time of diagnosis. The surgical procedures used to treat the patients, excluding the patients without surgical treatment (biopsy only), were classified by the margin as wide resection or not wide resection (including intralesional and marginal) according to the definition of Enneking and Maale [52]. Seven cases (15.9%) received a biopsy only, while 24 (54.5%) and 13 (29.5%) cases received wide or not wide resection, respectively. Wide resection was considered to be curative surgical treatment, whereas not wide resection and biopsy only were considered to be not curative treatment. Additionally, 11 out of 44 (25.0%) patients received chemotherapy, whereas 14 out of 44 (31.8%) patients received radiation therapy.

The follow-up period was dated from the time of diagnosis, the median follow-up period was 24 months, and the mean follow-up period was 37 months. Overall survival was recorded up until the time of death.

Immunohistochemical Analysis of COX-2 Expression in Tumor Samples

All the specimens used in the present study were resected before the preoperative chemo- and/or radiotherapy. Immunohistochemical analysis was performed on the tissue sections from formalin-fixed, paraffin-embedded blocks using the streptavidin-biotin complex (SABC) method. The mouse monoclonal anti-COX-2 antibody (clone 4H12; diluted 1:100; Novocastra, Newcastle upon Tyne, UK) was used in this study. The immunohistochemical results were evaluated by two investigators (H.H, an expert pathologist, and MH) who were unaware of the clinical status of the patients. The sections were examined using a multi-head microscope, and a consensus judgment was adopted as the proper immunohistochemical score of the tumor based on the proportion of stained tumor cells, as follows: 0, no stained tumor cells; 1+, less than 10% of all tumor cells stained; 2+, 10–50% of all tumor cells stained; 3+, 50–90% of all tumor cells stained; 4+, more than 90% of all tumor cells stained. Immunohistochemical scores of 3+ and 4+ (≥50% positive cells) were regarded as indicating the overexpression of COX-2.
Peptide Institute, Inc. (Osaka, Japan) and were dissolved in dimethyl sulfoxide (DMSO) as stock solutions.

Measurement of Etoalac-induced Cell Death in vitro
Cell viability was assessed using a cell proliferation reagent, WST-1 (Roche Diagnostics, Mannheim, Germany) [53]. FMS-1 and FPS-1 cells were seeded in 96-well plates (BD Falcon 353072, BD Biosciences, Franklin Lakes, NJ, USA) at a dose of $1.0 \times 10^4$ cells/well and incubated for 24 h at 37°C in 100 μl of phenol-red-free RPMI-1640 medium (Sigma R7509) supplemented with 10% FCS, 50 units/ml penicillin G, 50 μg/ml streptomycin, and 200 mM L-glutamine. FMS-1 and FPS-1 cells were treated by adding etodolac and then were dissolved and diluted to the desired concentration by 1 μl of 99.5% ethanol with 49 μl of culture medium (final concentration of ethanol: 0.67% or less), at final concentrations of 0 (control), 0.125, 0.25, 0.5, and 1 mM. At 24, 48, and 72 h after etodolac treatment, 15 μl of WST-1 reagent was added to each well, and the plates were incubated for 2 h at 37°C. The plates were then shaken for 1 min at room temperature, and the absorbance of 450–655 nm was measured using a multi-well ELISA reader (Microplate Reader, Model 550, Bio-Rad Laboratories, Hercules, CA, USA).

Morphological Analysis and DNA Fragmentation Analysis of Dead Cells
FMS-1 and FPS-1 cells were seeded in 6-well plates (BD Falcon 353046) at a dose of $5.0 \times 10^5$ cells/well and incubated for 24 h at 37°C in 5 ml of culture medium. Cells were treated by adding etodolac, dissolved and diluted to the desired concentration by 50 μl of 99.5% ethanol (final concentration of ethanol: 0.99% or less), at a final concentration of 0 (control) or 1 mM. At 24, 48, and 72 h after etodolac treatment, cells were removed using a rubber policeman. For morphological analysis of dead cells, 50 μl of the cell suspension was cytospun on silane-coated slides, which were stained by May-Giemsa staining and observed by two investigators (HH and MH). Suspended cells were washed in ice-cold phosphate-buffered saline (PBS) twice and pelleted by centrifugation. To detect the desired concentration by 1 μl of 99.5% ethanol with 49 μl of culture medium (final concentration of ethanol: 0.67% or less), at final concentrations of 0 (control), 0.125, 0.25, 0.5, and 1 mM. At 24, 48, and 72 h after etodolac treatment, 15 μl of WST-1 reagent was added to each well, and the plates were incubated for 2 h at 37°C. The plates were then shaken for 1 min at room temperature, and the absorbance of 450–655 nm was measured using a multi-well ELISA reader.

Data Analysis
In the clinicopathological analysis, Pearson’s chi-square test was used to examine correlations between two dichotomous variables. The overall survival curves were calculated using the Kaplan-Meier method, and the differences were compared by the logrank test. The Cox proportional hazards model was carried out to estimate the hazard ratios for positive risk factors for death.

In the in vitro examinations, all data were summarized as the means ± SD. Statistical analysis was performed using an unpaired Student’s t-test.

In all examinations, P<0.05 was considered statistically significant. The data analysis was performed using the JMP 9.0 statistical software package (SAS Institute, Cary, NC, USA).

Ethics Statement
This study was approved by the ethical review committee of Fukushima Medical University (No. 1076). Written informed consent for study inclusion was obtained from all patients and/or their families.

Acknowledgments
The authors would like to thank Ms. Michiko Sato and Ms. Hiromi Kaneko for their skillful technical assistance.

Author Contributions
Conceived and designed the experiments: MH T. Tajino S. Konno S. Kikuchi MA HH. Performed the experiments: MH HH. Analyzed the data: MH T. Tajino. Contributed reagents/materials/analysis tools: HY MY Kikuchi MA HH. Performed the experiments: MH HH. Analyzed the data: MH T. Tajino. Contributed reagents/materials/analysis tools: HY MY Kikuchi MA HH T. Tajino.

References
1. Nielsen GP, Antonescu CR, Lothe RA (2013) Malignant peripheral nerve sheath tumour. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft tissue and bone, 4th ed. Lyon: IARC. 187–189.
2. Weiss SW, Goldblum JR (2007) Malignant tumors of the peripheral nerves. In: Weiss SW, Goldblum JR, editors. Enzinger and Weiss’s soft tissue tumors, 5th ed. Philadelphia: Mosby/Elsevier. 903–917.
3. Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN (2008) Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J Surg Oncol 97: 340–349.
4. Vanet JR, Bakkal BS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97–120.
5. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, et al. (1998) Cyclooxygenase in biology and disease. FASEB J 12: 1063–1073.
Cyclooxygenase-2 Expression in Human MPNST

6. Endo M, Matsumura T, Yamaguchi T, Yamauchi U, Morimoto Y, et al. (2006) Cyclooxygenase-2 overexpression associated with a poor prognosis in chondrosarcoma. Hum Pathol 37: 471–476.

7. Rodriguez NI, Hoots WK, Koshima NV, Morales-Arias JA, Arndt CA, et al. (2008) COX-2 expression correlates with survival in patients with osteosarcoma lung metastases. J Pediatr Hematol Oncol 30: 507–512.

8. Urakawa H, Nishida Y, Naruse T, Nakaishi H, Ishiguro N (2009) Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study. Clin Orthop Relat Res 467: 2982–2986.

9. Boulthcve JA, Soloviev NY, Kushlin SK, Mahson AN (2010) Expression of molecular markers in the tumor and survival prognosis in osteosarcoma. Bull Exp Biol Med 150: 237–242.

10. Lee CH, Roh JW, Choi JS, Kang S, Park IA, et al. (2011) Cyclooxygenase-2 is an independent predictor of poor prognosis in uterine leiomyosarcomas. Int J Gynecol Cancer 21: 668–672.

11. Wang D, DuBois RN (2006) Prostaglandins and cancer. Gut 55: 115–122.

12. Moalic-Juge S, Liagre B, Duval R, Corbiere C, Bianchi A, et al. (2002) The anti-angiogenesis in chondrosarcoma and their relation to prognosis. J Bone Joint Surg Am 92: 1738–1746.

13. Moalic S, Liagre B, Le Bail JC, Beneytout JL (2001). Dose-dependent modulation of apoptosis and cyclooxygenase-2 expression in human 1547 osteosarcoma cells by NS-398, a selective cyclooxygenase-2 inhibitor. Int J Oncol 10: 533–540.

14. Dickens DS, Kozielski R, Leavey PJ, Timmons C, Cripe TP (2003) Establishment of a selective cyclooxygenase-2 inhibitor, NS-398, inhibits growth by cell cycle arrest in a human malignant fibrous histiocytoma cell line. Anticancer Res 23: 4671–4676.

15. Naruse T, Nishida Y, Hono K, Ishiguro N (2006) Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis 27: 584–592.

16. Hakozaki M, Hojo H, Kikuchi S, Abe M (2007) Endotox, a selective cyclooxygenase-2 inhibitor, induces apoptosis by activating caspases in human malignant rhabdoid tumor cells (FRTK-1). Oncol Rep 17: 169–173.

17. Mai I, Recenti R, Silvestri S, Pinzani P, Pepi M, et al. (2007) Expression of cyclooxygenase-2 in osteosarcoma of bone. Appl Immunohistochem Mol Morphol 15: 79–76.

18. Liu B, Shi ZL, Feng J, Tao HM (2008) Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Cell Biol Int 32: 494–501.

19. Schrage YM, Machado I, Meijer D, Briaire-de Bruijn I, van den Akker BE, et al. (2001) Selective cyclooxygenase-2 inhibitor, NS398, inhibits growth of PI3K/Akt. Cell Biol Int 32: 494–501.

20. Lee CH, Roh JW, Choi JS, Kang S, Park IA, et al. (2011) Cyclooxygenase-2 is an independent predictor of poor prognosis in uterine leiomyosarcomas. Int J Gynecol Cancer 21: 668–672.

21. Reed S, Li H, Li C, Lin J (2011) Celecoxib inhibits STAT3 phosphorylation and characterizations of a new cell line, FPS-1, derived from human undifferentiated pleomorphic sarcoma, overexpressing epidermal growth factor receptor. Int J Oncol 39: 1253–1262.

22. Yamashita H, Osaki M, Honjo S, Yoshida H, Teshima R, et al. (2003) A selective cyclooxygenase-2 inhibitor, NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bel-2 expression in LNCaP cells. Cancer Res 53: 4245–4249.

23. Tang X, Sun YJ, Hall E, Kuo MT, Sinicrope F (2002) Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 62: 4903–4908.

24. Carmony Son EE, Miller BJ, Scarborough MT, Reith J, Parker Gibbs C (2011) Cyclooxygenase-2 expression is not associated with clinical outcome in synovial sarcoma. Oncol Rep 26: 1513–1517.

25. Sutton KM, Wright M, Foulgren G, Towle CA, Mankin HJ (2004) Cyclooxygenase-2 expression in chondrosarcoma. Oncology 66: 275–280.

26. Anghileri M, Mocci R, Fiore M, Mariani L, Ferrari A, et al. (2006) Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 107: 1065–1074.

27. Nakagawa SA, Lopes A, Lopes de Carvalho A, Rossi BM, Wernert da Cunha I, et al. (2010) Nitric oxide synthases, cyclooxygenase-2, nitrotyrosine, and angiogenesis in chondrosarcoma and their relation to prognosis. J Bone Joint Surg Am 92: 1738–1746.